These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19935376)

  • 1. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome.
    Selzner N; Renner EL; Selzner M; Adeyi O; Kashfi A; Therapondos G; Girgrah N; Herath C; Levy GA; Lilly L
    Transplantation; 2009 Nov; 88(10):1214-21. PubMed ID: 19935376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.
    Calmus Y; Duvoux C; Pageaux G; Wolf P; Rostaing L; Vanlemmens C; Botta-Fridlund D; Dharancy S; Gugenheim J; Durand F; Néau-Cransac M; Boillot O; Chazouillères O; Samelson L; Boudjema K; Samuel D
    J Hepatol; 2012 Sep; 57(3):564-71. PubMed ID: 22613001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation.
    Ueda Y; Takada Y; Marusawa H; Egawa H; Uemoto S; Chiba T
    Transplantation; 2010 Sep; 90(6):661-5. PubMed ID: 20110853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
    Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection.
    Duvoux C; Villamil F; Renner EL; Grazi GL; Firpi RJ; Pageaux G; Mulhaupt B; Schirm F; Rauer B; Bernhardt P; Levy G
    Ann Transplant; 2015 Jan; 20():25-35. PubMed ID: 25588713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
    Nair S; Lipscomb J; Eason J
    Transplantation; 2008 Aug; 86(3):418-22. PubMed ID: 18698245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
    El-Hamamsy M; Montasser IF; Mansy AE; Nabet DE; El-Meteini M
    J Clin Pharm Ther; 2019 Jun; 44(3):447-453. PubMed ID: 30714175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience.
    Jain A; Sharma R; Ryan C; Safadjou S; Kashyap R; Mantry P; Maliakkal B; Orloff M
    Clin Transplant; 2010; 24(1):104-11. PubMed ID: 19239480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
    Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
    Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation.
    Tamè M; Buonfiglioli F; Del Gaudio M; Lisotti A; Cecinato P; Colecchia A; Azzaroli F; D'Errico A; Arena R; Calvanese C; Quarneti C; Ballardini G; Pinna AD; Mazzella G
    World J Gastroenterol; 2013 Aug; 19(32):5278-85. PubMed ID: 23983430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation.
    Ueda Y; Takada Y; Haga H; Nabeshima M; Marusawa H; Ito T; Egawa H; Tanaka K; Uemoto S; Chiba T
    Transplantation; 2008 Mar; 85(6):855-62. PubMed ID: 18360268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.
    Rodriguez-Luna H; Khatib A; Sharma P; De Petris G; Williams JW; Ortiz J; Hansen K; Mulligan D; Moss A; Douglas DD; Balan V; Rakela J; Vargas HE
    Transplantation; 2004 Jan; 77(2):190-4. PubMed ID: 14742979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
    Dhanasekaran R; Sanchez W; Mounajjed T; Wiesner RH; Watt KD; Charlton MR
    Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M; Fernandez JR; Suarez MJ; Gastaca M; Bustamante J; Pijoan JI; Montejo M; Valdivieso A; Ruiz P; Gonzalez J; Ortiz de Urbina J
    Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C.
    Kornberg A; Küpper B; Tannapfel A; Thrum K; Bärthel E; Habrecht O; Settmacher U
    Transplantation; 2008 Aug; 86(3):469-73. PubMed ID: 18698252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation.
    Picciotto FP; Tritto G; Lanza AG; Addario L; De Luca M; Di Costanzo GG; Lampasi F; Tartaglione MT; Marsilia GM; Calise F; Cuomo O; Ascione A
    J Hepatol; 2007 Mar; 46(3):459-65. PubMed ID: 17196700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation.
    Dinges S; Morard I; Heim M; Dufour JF; Müllhaupt B; Giostra E; Clavien PA; Mentha G; Negro F;
    Transpl Infect Dis; 2009 Feb; 11(1):33-9. PubMed ID: 19144096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.